PRESENTED AT AACR 2024

Patient-derived organoids as a reliable screening platform for assessing ADC efficacy and specificity

Antibody-drug conjugates (ADCs) are a new class of pharmaceutical drugs designed to deliver cytotoxic agents to cells expressing specific antigens selectively. Based on Paul Ehrlich’s “magic bullet” concept, ADCs are designed to target cancer cells, minimizing systemic toxicity typical of conventional chemotherapy. ADCs structurally consist of a particular monoclonal antibody linked to a cytotoxic agent. Patient-derived Organoids (PDOs) provide a new tool for studying cancer biology and patient stratification. PDOs are adult stem cell-based culture systems maintaining the patient-specific genetic and phenotypic characteristics, including surface marker expression.

Download this poster to discover:

• The application of a patient-derived organoid platform for ADC screening
• The established readouts used for ADC target expression and tumor organoid killing
• The dose-response data of a target antigen-directed ADC in a panel of colorectal cancer PDOs